The role of the Hippo pathway on mammalian organ size, progenitor cells and cance

Information

  • Research Project
  • 8403498
  • ApplicationId
    8403498
  • Core Project Number
    R01CA131426
  • Full Project Number
    4R01CA131426-06
  • Serial Number
    131426
  • FOA Number
    PA-07-187
  • Sub Project Id
  • Project Start Date
    1/1/2009 - 16 years ago
  • Project End Date
    12/31/2013 - 11 years ago
  • Program Officer Name
    WATSON, JOANNA M.
  • Budget Start Date
    1/1/2013 - 12 years ago
  • Budget End Date
    12/31/2013 - 11 years ago
  • Fiscal Year
    2013
  • Support Year
    06
  • Suffix
  • Award Notice Date
    12/28/2012 - 12 years ago

The role of the Hippo pathway on mammalian organ size, progenitor cells and cance

DESCRIPTION (provided by applicant): The Drosophila Hippo pathway regulates organ size through regulation of the transcriptional activator Yorkie. Interestingly, expression of the mammalian ortholog of Yorkie, YAP1, is enriched in stem cells and amplified in cancer. Our long-term goal in this project is to gain insight into the role of the Hippo signaling pathway in mammalian organ size control, stem cells and cancer. The specific hypothesis is that the Hippo pathway acts on stem cell compartments and expands undifferentiated progenitor cells when needed during tissue growth, and during tumorigenesis. The specific aims are: 1. Effect of Hippo pathway on stem cells. We will analyze effects of YAP1 on intestinal stem cells in vitro and in vivo. 2. Role of YAP1 on tumorigenesis. YAP1 activation leads to uncontrolled expansion of progenitor cells. We will analyze how YAP1 activation impacts on tumorigenesis and the requirement for YAP1 to maintain a cancerous state. 3. Identify downstream effectors of YAP1. YAP1 acts as a transcriptional coactivator. Preliminary data suggests that this may involve the Notch signaling pathway. We will analyze which transcription factor and transcriptional targets it activates.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R01
  • Administering IC
    CA
  • Application Type
    4
  • Direct Cost Amount
    189199
  • Indirect Cost Amount
    15136
  • Total Cost
    204335
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    396
  • Ed Inst. Type
  • Funding ICs
    NCI:204335\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    MONC
  • Study Section Name
    Molecular Oncogenesis Study Section
  • Organization Name
    NETHERLANDS CANCER INSTITUTE
  • Organization Department
  • Organization DUNS
    419693502
  • Organization City
    AMSTERDAM
  • Organization State
  • Organization Country
    NETHERLANDS
  • Organization Zip Code
    1066 CX
  • Organization District
    NETHERLANDS